BR112022009938A2 - Compostos macrocíclicos substituídos e métodos de tratamento relacionados - Google Patents

Compostos macrocíclicos substituídos e métodos de tratamento relacionados

Info

Publication number
BR112022009938A2
BR112022009938A2 BR112022009938A BR112022009938A BR112022009938A2 BR 112022009938 A2 BR112022009938 A2 BR 112022009938A2 BR 112022009938 A BR112022009938 A BR 112022009938A BR 112022009938 A BR112022009938 A BR 112022009938A BR 112022009938 A2 BR112022009938 A2 BR 112022009938A2
Authority
BR
Brazil
Prior art keywords
treatment methods
macrocyclic compounds
related treatment
substituted macrocyclic
substituted
Prior art date
Application number
BR112022009938A
Other languages
English (en)
Inventor
D Pennington Lewis
Choi Younggi
Huynh Hoan
M Aquila Brian
Mugge Ingo
Hu Yuan
r woods James
A Valiulin Roman
Kenneth Raymer Brian
Martin Bentzien Jorg
R Hale Michael
Ward Lehmann Jonathan
Matharu Daljit
Karra Srinivasa
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of BR112022009938A2 publication Critical patent/BR112022009938A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS MACROCÍCLICOS SUBSTITUÍDOS E MÉTODOS DE TRATAMENTO RELACIONADOS. A presente invenção fornece os compostos (I) e (II) úteis para o tratamento de narcolepsia ou cataplexia em um indivíduo em necessidade do mesmo. Composições farmacêuticas e métodos relacionados também são fornecidos na presente invenção.
BR112022009938A 2019-11-25 2020-11-25 Compostos macrocíclicos substituídos e métodos de tratamento relacionados BR112022009938A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939825P 2019-11-25 2019-11-25
US202063030979P 2020-05-28 2020-05-28
PCT/US2020/062320 WO2021108628A1 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment

Publications (1)

Publication Number Publication Date
BR112022009938A2 true BR112022009938A2 (pt) 2022-09-13

Family

ID=73856348

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009938A BR112022009938A2 (pt) 2019-11-25 2020-11-25 Compostos macrocíclicos substituídos e métodos de tratamento relacionados

Country Status (11)

Country Link
US (2) US11542276B2 (pt)
EP (1) EP4065585A1 (pt)
JP (1) JP2023502441A (pt)
KR (1) KR20220106793A (pt)
CN (1) CN114761412B (pt)
AU (1) AU2020394444A1 (pt)
BR (1) BR112022009938A2 (pt)
CA (1) CA3155885A1 (pt)
IL (1) IL293240A (pt)
MX (1) MX2022006206A (pt)
WO (1) WO2021108628A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114761412B (zh) 2019-11-25 2024-10-11 阿尔克姆斯有限公司 取代的大环化合物和相关治疗方法
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
EP4247801A1 (en) * 2020-11-23 2023-09-27 Merck Sharp & Dohme LLC 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
EP4329877A1 (en) * 2021-04-26 2024-03-06 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
WO2022251304A1 (en) * 2021-05-26 2022-12-01 Alkerme, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
CA3219506A1 (en) * 2021-05-26 2022-12-01 Hoan Huynh Substituted fused bicyclic macrocyclic compounds and related methods of treatment
TW202400606A (zh) * 2022-03-01 2024-01-01 英商歐瑞夏治療公司 中環或大環之經苄基取代之雜環衍生物及相關用途
WO2024095158A1 (en) * 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2024112899A1 (en) * 2022-11-23 2024-05-30 Vertex Pharmaceuticals Incorporated Substituted macrocyclic amine modulators of orexin receptor 2
WO2024160822A1 (en) 2023-01-31 2024-08-08 Jazz Pharmaceuticals Ireland Limited Macrocyclic orexin receptor agonists and uses thereof
WO2024189597A1 (en) 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
CA2307622A1 (en) 1997-10-31 1999-05-14 Biomira Inc. Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
AU2903999A (en) 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
US6492492B1 (en) 1998-04-03 2002-12-10 University Of Washington Circularly permuted biotin binding proteins
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
EP1257574A1 (en) 2000-02-11 2002-11-20 Maxygen Aps Improved interleukin 10
AU2001256981A1 (en) 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
US20040076991A1 (en) 2001-02-06 2004-04-22 Carr Francis J. Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity
AU2002321760B9 (en) 2001-07-20 2008-06-12 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ538629A (en) 2002-08-09 2008-05-30 Recopharma Ab Mucin-immunoglobulin fusion proteins
WO2004044006A1 (en) 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2005034863A2 (en) 2003-10-03 2005-04-21 Jarikuma Corporation Countermeasures against malaria
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
WO2006040182A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
RU2007123604A (ru) 2004-11-24 2008-12-27 Тэракайн Корпорэйшн (Us)Тэракайн Корпорэйшн (Us) Имплантат для внутриглазной доставки лекарственных средств
AU2006216651A1 (en) 2005-02-23 2006-08-31 Prexa Pharmaceuticals, Inc. Multimediator dopamine transport inhibitors, and uses related thereto
ES2359645T3 (es) 2005-08-12 2011-05-25 Riken Glucoproteína de tipo mucina y su uso.
WO2007063907A1 (ja) 2005-11-30 2007-06-07 Shionogi & Co., Ltd. ペプチド糖鎖付加体およびそれを有効成分とする医薬
DE602005015733D1 (de) 2005-12-02 2009-09-10 Apceth Gmbh & Co Kg Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
WO2008133928A2 (en) 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
RU2543157C2 (ru) 2008-06-17 2015-02-27 Глитек,Инк. Гликозилированный пептид glp-1
CA2760687A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
MX2011013884A (es) 2009-06-26 2012-02-01 Pfizer Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
ME02505B (me) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
EP2457579A1 (en) 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP5976011B2 (ja) 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
JP6111276B2 (ja) 2012-03-17 2017-04-05 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーション制約された全合成されたマクロ環化合物
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
JP6234446B2 (ja) 2012-06-08 2017-11-22 アルカーメス，インコーポレイテッド ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド
CA2878587A1 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
SG11201408526SA (en) 2012-08-08 2015-03-30 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
AU2014257123A1 (en) 2013-04-24 2015-10-15 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015017548A2 (en) 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
MX2016007661A (es) 2013-12-12 2017-01-06 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo.
RU2016135788A (ru) 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
EP3191468B1 (en) 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituted 2-azabicycles and their use as orexin receptor modulators
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2016101119A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2016199906A1 (ja) 2015-06-12 2016-12-15 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
KR102426986B1 (ko) * 2015-06-17 2022-07-28 화이자 인코포레이티드 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
CA2995997A1 (en) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
JP6847954B2 (ja) * 2015-12-18 2021-03-24 ノバルティス アーゲー キナーゼ阻害剤としての三環式化合物および組成物
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
AU2017291321B2 (en) 2016-06-22 2020-06-18 Alkermes, Inc. Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
WO2018164192A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
UA125597C2 (uk) 2017-08-03 2022-04-27 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука та її застосування
EP3663281B1 (en) 2017-08-03 2022-12-28 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP6874217B2 (ja) 2017-09-28 2021-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なｎ−（２，２−ジフルオロエチル）−ｎ−［（ピリミジニルアミノ）プロパニル］アリールカルボキサミド
US11673867B2 (en) 2017-12-12 2023-06-13 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
CN112165940A (zh) 2018-03-27 2021-01-01 德克萨斯州立大学董事会 Ox2r化合物
EP3816154A4 (en) 2018-06-29 2022-03-30 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3895707B1 (en) 2018-12-12 2023-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
CN118271298A (zh) 2019-01-31 2024-07-02 武田药品工业株式会社 杂环化合物及其用途
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3154320A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
CN114761412B (zh) 2019-11-25 2024-10-11 阿尔克姆斯有限公司 取代的大环化合物和相关治疗方法
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
US20230029486A1 (en) 2020-01-10 2023-02-02 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
EP4151277A4 (en) 2020-07-17 2024-06-26 Eisai R&D Management Co., Ltd. SUBSTITUTED PIPERIDINE COMPOUND AND ITS APPLICATION
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑
US20230257348A1 (en) 2020-08-18 2023-08-17 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
EP4208444A1 (en) 2020-09-03 2023-07-12 Orexia Therapeutics Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022051583A1 (en) 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
KR20230104193A (ko) 2020-11-02 2023-07-07 머크 샤프 앤드 돔 엘엘씨 마크로시클릭 우레아 오렉신 수용체 효능제
EP4247801A1 (en) 2020-11-23 2023-09-27 Merck Sharp & Dohme LLC 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
EP4255429A1 (en) 2020-12-03 2023-10-11 Merck Sharp & Dohme LLC 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4262788A1 (en) 2020-12-16 2023-10-25 Merck Sharp & Dohme LLC Urea orexin receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN117015526A (zh) 2021-03-03 2023-11-07 研究三角协会 作为食欲素受体激动剂的芳基磺酰胺
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
CN117616030A (zh) 2021-05-03 2024-02-27 爵士制药爱尔兰有限公司 食欲素受体激动剂及其用途

Also Published As

Publication number Publication date
CA3155885A1 (en) 2021-06-03
WO2021108628A1 (en) 2021-06-03
US12054495B2 (en) 2024-08-06
US20230339969A1 (en) 2023-10-26
US20210155636A1 (en) 2021-05-27
AU2020394444A1 (en) 2022-05-19
EP4065585A1 (en) 2022-10-05
CN114761412A (zh) 2022-07-15
JP2023502441A (ja) 2023-01-24
KR20220106793A (ko) 2022-07-29
MX2022006206A (es) 2022-09-09
CN114761412B (zh) 2024-10-11
US11542276B2 (en) 2023-01-03
IL293240A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
BR112022009938A2 (pt) Compostos macrocíclicos substituídos e métodos de tratamento relacionados
BR112022007627A2 (pt) Compostos moduladores do glp-1r
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
BR112019001666A2 (pt) n-(fenilsulfonil)benzamidas e compostos relacionados como inibidores de bcl-2
BR112018008746A2 (pt) composições e métodos para a inibição de atividade de arginase
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
BR112016029318A2 (pt) tratamento de mielomas
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112018069976A2 (pt) anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo.
BR112018012177A2 (pt) ?moduladores de hidantação de canais kv 3?
BR112022019991A2 (pt) Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
BR112022008365A2 (pt) Inibidores de cd73
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112021022784A2 (pt) Composições e métodos para tratamento do câncer
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
BR112018072740A2 (pt) realçador de inibidores de homólogo 2 de zeste
BR112022000870A2 (pt) Métodos de tratamento ou prevenção da atrofia muscular espinhal

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ALKERMES, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]